Alvotech (ALVO) AI Stock Analysis

Alvotech is a pharmaceutical company that specializes in developing and manufacturing biosimilar medicines to expand access to affordable treatments globally. Founded in 2013 and based in Reykjavik, Iceland, the business targets therapeutic areas such as autoimmune diseases, eye disorders, bone conditions, and cancer. Key commercial and pipeline assets include AVT02, a biosimilar of Humira for inflammatory conditions, and AVT04, a biosimilar of Stelara for Crohn's disease and ulcerative colitis. In addition, Alvotech develops AVT06, targeting eye diseases like macular degeneration, preclinical candidate AVT03 referencing Xgeva and Prolia, alongside AVT05 and AVT23 for inflammatory and nasal conditions.

Alvotech delivered significant revenue growth from $36.8M in FY2021 to $586.3M in FY2025, recording a 5-year revenue CAGR of 54.5%. FY2025 marked its first positive annual net income of $27.9M, generating an operating margin of 13.3% and gross margin of 59.8%, compared to a net loss of -$231.9M in FY2024. However, results for the trailing twelve months show an operating margin of -11.1% and net loss represented by an EPS of -$0.66 on revenue of $494.6M. For the latest quarter ended June 30, 2026, quarterly revenue fell 38.9% year-over-year, while quarterly earnings dropped 99.0% year-over-year.

As of June 30, 2026, Alvotech held $142.8M in cash and short-term investments against total debt of $1.45B, resulting in net debt of $1.31B. The company recorded negative shareholders' equity of -$191.5M out of $1.59B in total assets, while maintaining a current ratio of 1.65. Operating cash flow in FY2025 was -$50.2M, alongside capital expenditures of $64.5M, which contributed to a free cash flow deficit of -$114.7M. Additionally, Alvotech's share count increased 1041.8% over the past 5 years.

At $5.00 per share, Alvotech carries a market capitalization of $1.78B and an enterprise value of $3.39B. Its forward P/E of 15.2x and price-to-sales ratio of 3.6x sit below the median of its US-listed Healthcare peers, which stand at 17.3x and 4.1x, respectively. Conversely, its EV-to-EBITDA multiple of 22.3x trades at a premium to the peer median of 12.0x. Over the past year, ALVO shares declined 42.9%, trailing the S&P 500 return of 16.8%, and the stock is down 49.1% over five years compared to an 83.0% gain for the benchmark index.

Wall Street coverage consists of 4 Strong Buy, 2 Buy, and 1 Hold ratings, with zero Sell recommendations. The consensus mean price target of $6.80 implies an upside of 36.0% relative to the last closing price of $5.00. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $659.3M and an EPS of -$0.02. For the following fiscal year, 5 analysts project revenue of $775.7M and an EPS of $0.23. The company has beaten EPS expectations in 1 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Alvotech (ALVO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALVO income statement, ALVO balance sheet, ALVO key metrics, ALVO analyst forecast, ALVO chart. See the ALVO stock overview for the latest quote and news.